{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:19:37Z","timestamp":1780449577889,"version":"3.54.1"},"reference-count":36,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,10,31]]},"DOI":"10.5582\/bst.2025.01157","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:07:15Z","timestamp":1753222035000},"page":"581-588","source":"Crossref","is-referenced-by-count":1,"title":["Compare antiretroviral drug concentrations in hair and plasma across EFV-based regimens in China"],"prefix":"10.5582","volume":"19","author":[{"given":"Yuan","family":"Guan","sequence":"first","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China."},{"name":"Beijing Center for Disease Prevention and Control, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tao","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlu","family":"Jia","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Yunnan Provincial Infectious Diseases Hospital, Kunming, Yunnan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People&apos;s Hospital of Wenshan Prefecture, Wenshan, Yunnan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhan","sequence":"additional","affiliation":[{"name":"Calibra Lab in DIAN Diagnostics, Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Calibra Lab in DIAN Diagnostics, Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Yu","sequence":"additional","affiliation":[{"name":"Calibra Lab in DIAN Diagnostics, Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kumar L, Verma S, Prasad DN, Bhardwaj A, Vaidya B, Jain AK. Nanotechnology: a magic bullet for HIV AIDS treatment. Artif Cells Nanomed Biotechnol. 2015; 43:71-86.","DOI":"10.3109\/21691401.2014.883400"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Park TE, Mohamed A, Kalabalik J, Sharma R. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther. 2015; 13:1195-1212.","DOI":"10.1586\/14787210.2015.1075393"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lehmann C, Malin J, Su\u00e1rez I, F\u00e4tkenheuer G. Moderne HIV-Therapie [Modern HIV treatment]. Internist (Berl). 2019; 60:411-419.","DOI":"10.1007\/s00108-019-0564-0"},{"key":"4","unstructured":"4. Swinkels HM, Justiz Vaillant AA, Nguyen AD, Gulick PG. HIV and AIDS. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing, 2024."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Liu P, Liao L, Xu W, Yan J, Zuo Z, Leng X, Wang J, Kan W, You Y, Xing H, Ruan Y, Shao Y. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015. Medicine (Baltimore). 2018; 97:e13555.","DOI":"10.1097\/MD.0000000000013555"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tyagi A, Tong Y, Rabideau DJ, <i>et al<\/i>. Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa. Antivir Ther. 2022; 27:13596535221114822.","DOI":"10.1177\/13596535221114822"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Semengue ENJ, Fokam J, Etame NK, <i>et al<\/i>. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model. Viruses. 2022; 15:18.","DOI":"10.3390\/v15010018"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006; 28:468-473.","DOI":"10.1097\/01.ftd.0000211825.57984.41"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sundell J, Bienvenu E, \u00c4bel\u00f6 A, Ashton M. Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV. J Antimicrob Chemother. 2021; 76:2950-2957.","DOI":"10.1093\/jac\/dkab258"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. &quot;White coat compliance&quot; limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008; 9:238-246.","DOI":"10.1310\/hct0904-238"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, Carson KA, Siliciano RF, Flexner C. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006; 42:1189-1196.","DOI":"10.1086\/501458"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhang Q, Qiao S, Yang X, Li X. Antiretroviral Concentration in Hair as a Measure for Antiretroviral Medication Adherence: A Systematic Review of Global Literature. AIDS Behav. 2020; 24:311-330.","DOI":"10.1007\/s10461-019-02460-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pintye J, Bacchetti P, Teeraananchai S, <i>et al<\/i>. Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2017; 76:367-371.","DOI":"10.1097\/QAI.0000000000001527"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002; 137:696-697.","DOI":"10.7326\/0003-4819-137-8-200210150-00016"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chu L, Wu Y, Duan C, Yang J, Yang H, Xie Y, Zhang Q, Qiao S, Li X, Shen Z, Deng H. Simultaneous quantitation of zidovudine, efavirenz, lopinavir and ritonavir in human hair by liquid chromatography-atmospheric pressure chemical ionizationtandem mass spectrometry. J Chromatogr B AnalytTechnol Biomed Life Sci. 2018; 1097-1098:54-63.","DOI":"10.1016\/j.jchromb.2018.08.031"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chawana TD, Gandhi M, Nathoo K, Ngara B, Louie A, Horng H, Katzenstein D, Metcalfe J, Nhachi CFB; Adolescent Treatment Failure (ATF) study team. Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. J Acquir Immune Defic Syndr. 2017; 76:55-59.","DOI":"10.1097\/QAI.0000000000001452"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Methling M, Krumbiegel F, Hartwig S. Hair analysis of antidepressants and antipsychotics-Overview of quantitative data. Drug Test Anal. 2020; 12:659-676.","DOI":"10.1002\/dta.2784"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006; 370:17-49.","DOI":"10.1016\/j.cca.2006.02.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008; 22:3401-3409.","DOI":"10.1002\/rcm.3750"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gandhi M, Ameli N, Bacchetti P, <i>et al<\/i>. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009; 23:471-478.","DOI":"10.1097\/QAD.0b013e328325a4a9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Johnston J, Orrell C, Smith P, Joubert A, Wiesner L. A validated liquid chromatography\/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients. Rapid Commun Mass Spectrom. 2018; 32:657-664.","DOI":"10.1002\/rcm.8077"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wu Y, Chu L, Yang H, Wang W, Zhang Q, Yang J, Qiao S, Li X, Shen Z, Zhou Y, Liu S, Deng H. Simultaneous Determination of 6 Antiretroviral Drugs in Human Hair Using an LC-ESI+-MS\/MS Method: Application to Adherence Assessment. Ther Drug Monit. 2021; 43:756-765.","DOI":"10.1097\/FTD.0000000000000878"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shima N, Nitta A, Kamata T, Sasaki K, Matsuta S, Ishikawa A, Asai R, Wada M, Kakehashi H, Nakano S, Kamata H, Sato T, Tsuchihashi H, Miki A, Katagi M. Incorporation of zolpidem and methoxyphenamine into white hair strands after single administrations: Influence of hair pigmentation on drug incorporation. Forensic Sci Int. 2019; 301:67-75.","DOI":"10.1016\/j.forsciint.2019.05.013"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bernard L, Vuagnat A, Peytavin G, Hallouin MC, Bouhour D, Nguyen TH, Vild\u00e9 JL, Bricaire F, Raguin G, de Truchis P, Ghez D, Duong M, Perronne C. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Annals of Internal Medicine. 2002; 137:656-659.","DOI":"10.7326\/0003-4819-137-8-200210150-00009"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yan J, Liu J, Su B, Pan X, Wang Z, Wu J, Zhang J, Ruan Y, Hsi J, Liao L, Shao Y, Xing H. Lamivudine concentration in hair and prediction of virologic failure and drug resistance among HIV patients receiving free ART in China. Plos One. 2016; 11:e0154421.","DOI":"10.1371\/journal.pone.0154421"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, <i>et al<\/i>. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381:816-826.","DOI":"10.1056\/NEJMoa1904340"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen MH, Sharp GB, Huang Y, Greenblatt RM. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011; 52:1267-1275.","DOI":"10.1093\/cid\/cir131"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Vaughan TE, Weaver JC. Mechanism of transdermal drug delivery by electroporation. Methods Mol Med. 2000; 37:187-211.","DOI":"10.1385\/1-59259-080-2:187"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Avachat AM, Parpani SS. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerfaces. 2015; 126:87-97.","DOI":"10.1016\/j.colsurfb.2014.12.014"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lam K, Kraft WK, Zhan T, Lam E. Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial. ClinTransl Sci. 2024; 17:e13721.","DOI":"10.1111\/cts.13721"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ngara B, Zvada S, Chawana TD, Stray-Pedersen B, Nhachi CFB, Rusakaniko S. A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents. BMC Pharmacol Toxicol. 2020; 21:58.","DOI":"10.1186\/s40360-020-00437-y"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Tabb ZJ, Mmbaga BT, Gandhi M, Louie A, Kuncze K, Okochi H, Shayo AM, Turner EL, Cunningham CK, Dow DE. Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. AIDS. 2018; 32:1115-1123.","DOI":"10.1097\/QAD.0000000000001788"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wang PF, Neiner A, Kharasch ED. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry [published correction appears in Drug Metab Dispos. 2019; 47:1195-1205.","DOI":"10.1124\/dmd.119.086348"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Shah SA, Mullin R, Jones G, Shah I, Barker J, Petroczi A, Naughton DP. Simultaneous analysis of antiretroviral drugs abacavir and tenofovir in human hair by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2013; 74:308-313.","DOI":"10.1016\/j.jpba.2012.10.023"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Deshmukh N, Hussain I, Barker J, Petroczi A, Naughton DP. Analysis of anabolic steroids in human hair using LC-MS\/MS. Steroids. 2010; 75:710-714.","DOI":"10.1016\/j.steroids.2010.04.007"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. R\u00f6hrich CR, Dr\u00f6gem\u00f6ller BI, Ikediobi O, van der Merwe L, Grobbelaar N, Wright GE, McGregor N, Warnich L. CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women. AIDS Res Hum Retroviruses. 2016; 32:529-538.","DOI":"10.1089\/aid.2015.0048"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/5\/19_2025.01157\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:03:08Z","timestamp":1763179388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/5\/19_2025.01157\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01157","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"2025.01157"}}